Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
about
Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesteraseSwitching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.Cognitive-Enhancing Effect of Steamed and Fermented Codonopsis lanceolata: A Behavioral and Biochemical Study.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions?Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addictionRole of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's studyEquipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathologyRivastigmine in Alzheimer's disease: Cognitive function and quality of life.Targeting acetylcholinesterase to treat neurodegeneration.Cognitive-Enhancing Effect of Dianthus superbus var. Longicalycinus on Scopolamine-Induced Memory Impairment in MiceCognitive-Enhancing Effect of Aronia melanocarpa Extract against Memory Impairment Induced by Scopolamine in Mice.Steamed and Fermented Ethanolic Extract from Codonopsis lanceolata Attenuates Amyloid-β-Induced Memory Impairment in Mice.Rivastigmine in the treatment of Alzheimer's disease: an update.Treatment of Alzheimer's disease across the spectrum of severity.The Ameliorating Effect of Steamed and Fermented Codonopsis lanceolata on Scopolamine-Induced Memory Impairment in Mice.Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.Dual inhibition: a novel promising pharmacological approach for different disease conditions.Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy.Selective dual cholinesterase inhibitors from Aconitum laeve.Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.Design and Development of a Novel Chalcone Derivative as an Anticholinesterase Inhibitor for Possible Treatment of Dementia.Molecular dynamics simulation study and molecular docking descriptors in structure-based QSAR on acetylcholinesterase (AChE) inhibitors.Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.Inhibition of Cholinesterases and Some Pro-Oxidant induced Oxidative Stress in Rats Brain by Two Tomato (Lycopersicon Esculentum) Varieties.Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from Allanblackia monticola and Symphonia globulifera.Bioactive constituents of Salvia chrysophylla Stapf.Aqueous extracts of avocado pear (Persea americana Mill.) leaves and seeds exhibit anti-cholinesterases and antioxidant activities in vitro.Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.Hippeastrum reticulatum (Amaryllidaceae): Alkaloid Profiling, Biological Activities and Molecular Docking.Cognitive enhancing effect of the fermented Gumiganghwal-tang on scopolamine-induced memory impairment in mice.Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.Rivastigmine improves isolation rearing-induced prepulse inhibition deficits via muscarinic acetylcholine receptors in mice.BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.An electrochemical platform for acetylcholinesterase activity assay and inhibitors screening based on Michael addition reaction between thiocholine and catechol-terminated SAMs.Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer's disease.The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.
P2860
Q27684632-3933F2CC-82BE-498D-8DC0-4F6642FD1E73Q33750604-042E2591-0D7A-4393-8233-09140BE9BE23Q33852263-7E9D86A2-61C9-4F36-8D93-86C774304902Q34648742-02081626-3EE1-41A3-884E-DFA63F7AFE8BQ34771671-DB32E438-65DD-4D9F-B35A-7544D134F463Q35066849-6B0EFA1F-1323-4C03-9E7F-3FDB916EC0CDQ35792386-781C59A0-61F4-49E6-8303-BACB74CA5C63Q35863422-EAF2C8D9-AC1A-445F-8127-64C1D21AD00CQ36247233-AFEA493A-9890-4CE7-AD5F-22FB174D0E30Q36345411-FAB7476B-4B51-425A-A89D-5EF0514996E3Q36663678-DCAFCB1D-9065-4ABF-8373-7823A5699668Q36709537-4EAF4309-9978-458F-8E94-BCCAC9E9ECE9Q36879198-79E518FA-9927-4215-8105-CF9144A8DDCFQ36901383-3A6DEA72-7856-41AE-B1F4-BD385FAAA0E7Q36970193-BBBAA5CA-50B9-4239-8F08-418DC5EAA221Q37017260-96770A60-24CA-4408-8AE9-559ED0135D0AQ37017375-4F738222-1272-4542-9948-52FF57C0B396Q37054894-C5FD5E4A-E960-47BC-AC03-1B74B8C01253Q37707371-94153BF9-9388-4BDC-AE8A-DCB058A8FC8EQ37852762-5BA2218B-0FD7-4B2B-A0EF-605E09DD9950Q38126948-07075953-1670-4A4F-BFE9-DEF6BB3BB1E9Q38809154-00C3BE3C-9A03-473C-8E33-C7F0F02E0B21Q39136370-FA03B4E9-F4F4-4259-8701-2AAF8777DDA3Q41036141-3F9B29A2-4D86-4DA1-91CF-D4719539A26BQ44409699-BDBAA82B-6B06-47EB-B977-49B0BA466242Q44625738-413C0064-9169-4F65-81D0-9858C831FEE7Q45071385-A6F81BEA-D1A9-4D67-A2F1-4DA049CA56A1Q46250891-647C3453-476A-4A4B-9348-6FB42221A2ECQ46506487-712F73DB-E65D-418E-AB8C-D04C236D3F62Q46540939-C7DCF3CC-2D8E-4455-82B0-38AA0E7DE723Q46604622-CA37622F-4BE0-4CE7-B697-F45A665E80DEQ46804778-CA769DB7-8399-4BD8-A431-994D40462BD2Q47302195-A9093F74-B393-40A4-A31A-5F360B638F96Q48547781-6A2FD0AE-20CA-40C0-8687-4206AE28A533Q50192506-D3F81AC4-7167-4B20-8B0E-447D589A6143Q50764523-B369E611-D16A-427E-A18B-F7929CC7457BQ50800255-B22AA4EF-E977-4B88-A0FA-B8CEE586C136Q52729024-C299DA26-0C35-4F6D-BB2E-8D3E04992915Q53287162-EFE96285-B1A9-4CE0-9C4E-6108C2D80323Q53370114-F97033C0-D7AF-4C63-962B-28180ECA2053
P2860
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Advances in the treatment of A ...... ual cholinesterase inhibition.
@ast
Advances in the treatment of A ...... ual cholinesterase inhibition.
@en
Advances in the treatment of A ...... ual cholinesterase inhibition.
@nl
type
label
Advances in the treatment of A ...... ual cholinesterase inhibition.
@ast
Advances in the treatment of A ...... ual cholinesterase inhibition.
@en
Advances in the treatment of A ...... ual cholinesterase inhibition.
@nl
prefLabel
Advances in the treatment of A ...... ual cholinesterase inhibition.
@ast
Advances in the treatment of A ...... ual cholinesterase inhibition.
@en
Advances in the treatment of A ...... ual cholinesterase inhibition.
@nl
P356
P1433
P1476
Advances in the treatment of A ...... dual cholinesterase inhibition
@en
P2093
Ballard CG
P356
10.1159/000047952
P577
2002-01-01T00:00:00Z